Biogenetics company Klotho Neurosciences has announced plans to acquire assets from Turn Biotechnologies, marking a move in the development of longevity therapeutics.
Turn Biotechnologies is focused on induced pluripotent stem cells (iPSCs) and cellular reprogramming.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Klotho has signed a letter of intent (LOI) in this regard.
The cash and stock deal is contingent upon the completion of due diligence, the execution of a definitive agreement and fulfilment of typical closing conditions.
Under the LOI’s terms, Klotho would gain control of Turn’s Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system.
Developed at Stanford University in the US, and exclusively licensed by the institution, the ERA platform leverages the eTurna system.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThese technologies are intended for restoring the function of tissues and rejuvenating somatic cells, potentially leading to a variety of regenerative therapies in ophthalmology, dermatology, osteoarthritis, muscle health, immunology and amyotrophic lateral sclerosis (ALS).
A key aspect of the transaction is Klotho’s acquisition of an out-licensing and joint development partnership with a South Korean pharmaceutical company, which could be worth up to $300m.
This collaboration demonstrates the commercial interest in Turn’s platform, underscoring the wide-ranging potential of its technology.
Following the anticipated completion of the acquisition, Klotho plans to undergo rebranding to better represent its wider mission and therapeutic capabilities.
The company also plans to welcome key Turn Biotechnologies personnel from their management and research and development departments after the transaction is finalised.
Klotho Neurosciences CEO Dr Joseph Sinkule stated: “This LOI marks a transformative step for Klotho. The Klotho gene is often referred to as the ‘anti-aging gene,’ first identified for its ability to extend lifespan in animal models and protect against neurodegenerative diseases. Our company was founded on translating that science into therapies that combat age-related decline.
“By adding Turn’s ERA technology — which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age — together with the eTurna RNA lipid nanoparticle (LNP) delivery platform, we are expanding beyond a single Klotho gene into a powerful system of cellular rejuvenation.”
